Schedule 13D - Activist Investments
See all →NASDAQ
Perceptive Advisors LLC, along with its affiliates, has amended its Schedule 13D filing concerning Trinity Biotech plc, detailing changes to a convertible note and credit agreement.
Capital raise
NASDAQ
SCHEDULE 13D/A: Perceptive Funds Trim Trinity Biotech Stake Amid Price Decline
Perceptive Credit Holdings II, L.P. sold nearly 2 million American Depositary Shares of Trinity Biotech plc between December 2025 and January 2026, with prices declining significantly.
Worse than expected
NASDAQ
Perceptive Advisors and its funds have amended credit agreements with Trinity Biotech plc, converting significant debt obligations into potentially convertible equity, subject to a 9.9% beneficial ownership cap.
Capital raise
NASDAQ
DAYLI Filers report complete divestment of their beneficial ownership in Trinity Biotech plc following the 2025 MiCo IVD Purchase by AI n M.
NASDAQ
An amendment to Schedule 13D reports a change in MiCo IVD's management and confirms its 17.0% beneficial ownership in Trinity Biotech plc.
NASDAQ
AI n M net Ltd. has acquired MiCo IVD Holdings, LLC, making it a significant beneficial owner of 17.0% of Trinity Biotech plc's Class 'A' Ordinary Shares.
Schedule 13G - Passive Investments
NASDAQ
Novus Diagnostics Ltd. has reported a 5.99% beneficial ownership stake in Trinity Biotech PLC, holding 1,119,988 American Depositary Shares.